Allogene Therapeutics

NASDAQ
ALLO
Stock
Yield per half year: -13.58%
Dividend yield: 0%
Sector: Healthcare

Company Analysis Allogene Therapeutics

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Price (1.4 $) is less than fair price (2.23 $)

Disadvantages

  • Dividends (0%) are below the sector average (0.527%).
  • The stock's return over the last year (-47.76%) is lower than the sector average (-1.85%).
  • Current debt level 16.54% has increased over 5 years from 7.15%.
  • The company's current efficiency (ROE=-55.13%) is lower than the sector average (ROE=14.17%)

Similar companies

Illumina

Incyte

Amarin

ImmunoGen

2. Share price and performance

2.1. Share price

2.3. Market efficiency

Allogene Therapeutics Healthcare Index
7 days -1.4% 9.1% 1.2%
90 days -1.4% 4.9% 21.7%
1 year -47.8% -1.8% 21.8%

ALLO vs Sector: Allogene Therapeutics has significantly underperformed the "Healthcare" sector by -45.91% over the past year.

ALLO vs Market: Allogene Therapeutics has significantly underperformed the market by -69.52% over the past year.

Stable price: ALLO is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: ALLO with weekly volatility of -0.9185% over the past year.

3. Summary of the report

3.1. General

P/E: 0
P/S: 18595.67

3.2. Revenue

EPS -1.32
ROE -55.13%
ROA -43.24%
ROIC -29.87%
Ebitda margin -1106031.82%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Below fair price: The current price (1.4 $) is lower than the fair price (2.23 $).

Price significantly below the fair price: The current price (1.4 $) is 59.3% lower than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (64.15).

P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (90.03).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (0.969) is lower than that of the sector as a whole (18.96).

P/BV vs Market: The company's P/BV (0.969) is lower than that of the market as a whole (9.39).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (18595.67) is higher than that of the sector as a whole (32.77).

P/S vs Market: The company's P/S indicator (18595.67) is higher than that of the market as a whole (10.12).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (-1.75) is lower than that of the sector as a whole (274.79).

EV/Ebitda vs Market: The company's EV/Ebitda (-1.75) is lower than that of the market as a whole (50.91).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 1.96% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (1.96%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).

5.4. ROE

ROE vs Sector: The company's ROE (-55.13%) is lower than that of the sector as a whole (14.17%).

ROE vs Market: The company's ROE (-55.13%) is lower than that of the market as a whole (11.64%).

5.5. ROA

ROA vs Sector: The company's ROA (-43.24%) is lower than that of the sector as a whole (1.18%).

ROA vs Market: The company's ROA (-43.24%) is lower than that of the market as a whole (6.89%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (-29.87%) is lower than that of the sector as a whole (7.63%).

ROIC vs Market: The company's ROIC (-29.87%) is lower than that of the market as a whole (11.08%).

6. Finance

6.1. Assets and debt

Debt level: (16.54%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 7.15% to 16.54%.

Excess of debt: The debt is not covered by net income, percentage -35.23%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.527%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Allogene Therapeutics

9.3. Comments